Tag Archives: REGN

Best Safest Stocks To Buy Right Now

Nordea (OTCPK:NRBAY) is, for those unfamiliar, the biggest pan-Nordic banking group, having market shares of 15-30% in each of the four Nordic countries: Denmark, Finland, Norway, and Sweden. According to Global Financial Magazine, Nordea was ranked as the 29th safest bank globally in 2017. The ranking was based on the long-term foreign currency ratings issued by Fitch Ratings, Standard & Poor’s and Moody’s Investors Service.

Source: Company data

Another indicator of its safe-haven status is the fact that Nordeas junior subordinated bonds, or the so-called CoCos, are trading at just a 3.4% yield. For comparison, JPMorgans (JPM) CoCos are trading at a 5.5% yield.

Best Safest Stocks To Buy Right Now: Plains All American Pipeline L.P.(PAA)

Advisors’ Opinion:

  • [By Dustin Parrett]

    We think Plains All American Pipeline L.P. (NYSE: PAA) is one of the best oil stocks to buy this year. In fact, we see a scenario where PAA stock could jump 20% in 2017.

  • [By Dustin Parrett]

    Plains All American Pipeline (NYSE: PAA) controls 4 million barrels of crude oil and natural gas a day.

    And with higher oil prices and fewer restrictions leading to more drilling, PAA’s pipelines will be in demand in 2017.

  • [By Matthew DiLallo]

    One of the largest projects is the Saddlehorn Pipeline, which Magellan is building with Plains All American Pipeline (NYSE:PAA) and Anadarko Petroleum (NYSE:APC). Both Plains All American Pipeline and Magellan own 40% of the project, which puts their total investment at $230 million apiece. They expect the project to be fully operational early next year, which is noteworthy given its robust first-year economics. Magellan estimates that it will earn eight times EBITDA on the capital deployed, or roughly $28.8 million in annual EBITDA apiece for Magellan and Plains All American Pipeline on their investment.

Best Safest Stocks To Buy Right Now: Digirad Corporation(DRAD)

Advisors’ Opinion:

  • [By ]

    Some of these are even smaller nano-caps, such as medical device maker Digirad (Nasdaq: DRAD), whose entire market value is just $36 million.

    There is absolutely nothing wrong with small businesses. I own shares of quite a few in my personal account. But for the most part, I use them to fill out the growth sleeve of my portfolio and don’t consider them stable income producers.

Best Safest Stocks To Buy Right Now: Regeneron Pharmaceuticals, Inc.(REGN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) soared to the top of the S&P 500 today after a competitor’s competing drug failed a Phase 3 trial.

    Getty Images

    Regenerongained 3.8% to $387.10 today, while the S&P 500 declined 0.1% to 2,256.96.

    RBC’s Adnan Butt and Michael Yee offer their take:

    Two Phase 3 studies comparing Ophthotechs (OPHT) Fovista plus Lucentis to Lucentis alone did not meet the primary endpoint of demonstrating a better vision for the combination at 12 months. The improvements were 10.24 letters for the combo vs. 10.01 for Lucentis when the two Phase 3s were combined. Individually, one Phase 3 showed combo improvement of 10.74 letters vs. 9.82 letters alone and the second 9.91 letters vs. 10.36 letters with Lucentis alone. A third Phase 3 study combining Fovista with Eylea or Avastin is ongoing…

    Big overhang removed; [Regeneron] shares should be up and then continue to rise with the focus moving to dupilumab. Overhang was that Fovista success and approval could disrupt the market for Eylea as more docs tried combining nearly free Avastin (off-label) with Fovista to improve outcomes with patients. We had always argued that even under that scenario Eylea would be used since it is the most potent agent. We are buyers at current level especially ahead of the upcoming dupilumab launch.

    Regeneron’s market capitalization rose to $51.5 billion today from $39.3 billion yesterday. It reported net income of $636 million on sales of $4.1 billion in 2015.

  • [By Todd Campbell, Demitrios Kalogeropoulos, and Reuben Gregg Brewer]

    In the case of these three stocks, however, it may be worth taking a gamble. Our contributors think catalysts at Regeneron Pharmaceuticals (NASDAQ:REGN), Royal Dutch Shell (NYSE:RDS-B), and United Parcel Service (NYSE:UPS) can get them back to their winning ways. Read on to find out if these down-and-out stocks are right for your portfolio.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

  • [By Chris Lange]

    Shares of Amgen Inc. (NASDAQ: AMGN) saw a handy gain to close out the week after the company won a Delaware court ruling that blocked Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from selling their cholesterol-lowering drug in the United States. Essentially the court found that the drug Praluent actually infringed upon Amgens patents for its rival treatment Repatha.

Best Safest Stocks To Buy Right Now: Tantech Holdings Ltd.(TANH)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggestedshorting small cap China based carbon stock Tantech Holdings Ltd (NASDAQ: TANH):

    “The downtrend here is crystal clear; more of the same weakness is there on the earlier part of the chart you can’t see. What’s so compelling about the selloff is yesterday’s bar. The bulls tried to bounce back, but couldn’t… the buyers threw in the towel. TANH peeled back to close closer to the low than the high, and is following through — to the downside — today.”

Best Safest Stocks To Buy Right Now: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

Best Safest Stocks To Buy Right Now: Francesca's Holdings Corporation(FRAN)

Advisors’ Opinion:

  • [By Lisa Levin] Related LOV Match Group And Spark Networks: A Valentine's Day Case Study 20 Biggest Mid-Day Losers For Thursday
    Related VKTX 15 Biggest Mid-Day Losers For Tuesday 18 Biggest Mid-Day Losers For Wednesday Companies Reporting Before The Bell
    Canadian Solar Inc. (NASDAQ: CSIQ) is expected to report its quarterly earnings at $0.32 per share on revenue of $690.27 million.
    General Mills, Inc. (NYSE: GIS) is projected to report its quarterly earnings at $0.71 per share on revenue of $3.84 billion.
    Coca-Cola European Partners Plc (NYSE: CCE) is estimated to report its quarterly earnings at $0.45 per share on revenue of $2.72 billion.
    Lands' End, Inc. (NASDAQ: LE) is expected to report its quarterly earnings at $0.35 per share on revenue of $459.43 million.
    Francesca's Holdings Corp (NASDAQ: FRAN) is estimated to report its quarterly earnings at $0.37 per share on revenue of $145.91 million.
    Cheetah Mobile Inc (ADR) (NYSE: CMCM) is projected to report its quarterly earnings at $0.06 per share on revenue of $178.04 million.
    Neogen Corporation (NASDAQ: NEOG) is estimated to report its quarterly earnings at $0.27 per share on revenue of $90.05 million.
    Lennar Corporation (NYSE: LEN) is projected to post earnings for its first quarter.
    Fifth Street Asset Management Inc (NASDAQ: FSAM) is expected to report its quarterly earnings at $0.14 per share on revenue of $25.12 million.

     

  • [By Lisa Levin]

    Francesca's Holdings Corporation (NASDAQ: FRAN) was down, falling around 9 percent to $7.09 following downbeat quarterly earnings.

    Commodities

  • [By Paul Ausick]

    Francesca’s Holdings Corp. (NASDAQ: FRAN) dropped about 4.5% Monday to post a 52-week low of $5.68 after closing at $5.95 on Friday. The 52-week high is $19.50. Volume was around 2.7 million, more than double the daily average. The specialty retailer lowered its fourth-quarter outlook last Friday and the investor walkaway continues.

  • [By Ben Levisohn]

    Francesca’s Holdings (FRAN) has jumped 5.4% to $11.00 after beating earnings forecasts.

    Restoration Hardware (RH) has tumbled 20% to $28.92 after slashing its full-year guidance. Restoration Hardware was also cut to Market Perform from Outperform at Telsey Advisory Group.

stock market today chart

This morning, we added small cap mobile communication equipment and content stock KVH Industries, Inc (NASDAQ: KVHI) to our Elite Opportunity Pro (EOP) portfolio as the Company iswell positioned for industrial mobile connectivity growth over land and sea. KVH Industries is a leading provider of in-motion satellite TV and communications systems, having designed, manufactured, and sold more than 200,000 mobile satellite antennas for applications on vessels, vehicles and aircraft. The Company is also a leading news, music, and entertainment content provider to many industries including maritime, retail and leisure. In addition, Videotel (a KVH company) is a market-leading provider of training films, computer-based training and eLearning.

On the fundamental side, our EOP newsletter noted:

stock market today chart: U.S. Bancorp(USB)

Advisors’ Opinion:

  • [By John Maxfield]

    One of this era’s most successful bankers has decided to relinquish the reins. U.S. Bancorp (NYSE:USB) announced on Tuesday that chairman and CEO Richard Davis will step down from his role as CEO at the bank’s annual meeting in April. He’ll stay on as executive chairman of the board, while President and COO Andy Cecere will succeed him in the corner office.

  • [By Sarfaraz Khan]

    In addition to this, Warren Buffett has also built sizable positions in a number of major US banks.Wells Fargo (NYSE:WFC), U.S. Bancorp (NYSE:USB)and Goldman Sachs (NYSE:GS)have the leading positions in Berkshire Hathaways portfolio. In fact, Wells Fargo is Berkshire Hathaway’s second largest stock holding. In addition to this, Berkshire Hathaway also owns $5 billion worth of Bank of Americas preferred shares and warrants to buy 700 million of the banks ordinary shares at just $7.14 (current price $22.10) anytime until September 2021. These banks are positioned to become the biggest beneficiaries of the increase in interest rates. To get an idea of how this might happen, consider Bank of Americas forecast in which it predicted a $7.5 billion boost to annual net interest income following a 1-percentage-point increase in interest rates.

stock market today chart: CarMax Inc(KMX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    CarMax (KMX) gained 2.4% to $58 after beating earnings and sales forecasts.

    Constellation Brands (STZ) has rallied 4.7% to $169 after beating earnings forecasts and offering optimistic guidance.

  • [By Lisa Levin]

    CarMax, Inc (NYSE: KMX) reported better-than-expected earnings for its fourth quarter.

    CarMax reported Q4 earnings of $0.81 per share on revenue of $4.05 billion. Analysts expected earnings of $0.79 per share on revenue of $3.93 billion.

  • [By Craig Jones]

    Jon Najarian spoke about high options activity in CarMax, Inc (NYSE: KMX). He said traders are buying upside calls, the 75 strike calls and higher. Jon Najarian decided to buy calls in the name and he's planning to hold them for 10 days.

  • [By Ben Levisohn]

    Yesterday, I dubbed the selloff in auto stocks “car-pocalypse now,” as shares of everything car related tumbled following disappointing auto sales. Shares of General Motors (GM) and Ford Motor (F)? Check. Auto-part makers like BorgWarner (BWA)? Check. Used-car sellers like AutoNation (AN) and CarMax (KMX)? Check. Auto-part retailers like O’Reilly Automotive (ORLY) and AutoZone (AZO)? Oh yeah. So is it time to panic?

stock market today chart: iShares Core S&P Mid-Cap (IJH)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Lubar & Co., Inc’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Lubar+%26+Co.%2C+Inc

    These are the top 5 holdings of Lubar & Co., IncEnLink Midstream LLC (ENLC) – 1,882,007 shares, 37.97% of the total portfolio. Shares added by 0.40%Hallador Energy Co (HNRG) – 2,788,685 shares, 23.23% of the total portfolio. Vanguard Value ETF – DNQ (VTV) – 77,126 shares, 7.65% of the total portfolio. iShares Core S&P Mid-Cap (IJH) – 38,400 shares, 6.84% of the total portfolio. New PositionVanguard Mid-Cap Value ETF – DNQ (VOE) – 61,550 shares, 6.52% of the tota

stock market today chart: Ellie Mae, Inc.(ELLI)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Ellie Mae (ELLI) was downgraded to sector perform from outperform at RBC Capital. $90 price target. The company is leveraged to lower expected refinance activity, RBC said. 

  • [By Brian Stoffel]

    For a long time, low rates were a huge boon to Ellie Mae (NYSE:ELLI), which offers subscribers access to the Encompass platform. Encompass helps streamline the mortgage origination process.

  • [By Jason Hall, Brian Stoffel, and Brian Feroldi]

    With that idea in mind, we asked three of our top contributors to write about a stock they see as being a bargain today, and they gave us mortgage industry software lynchpinEllie Mae Inc(NYSE:ELLI), real estate holding companyStore Capital Corp(NYSE:STOR), and steelmaker extraordinaireNucor Corporation(NYSE:NUE).

  • [By Jason Moser]

     Not intimidated by the Fed’s 25-basis-point rate hike in December, Jason chose Ellie Mae (ELLI), a company with a leading cloud productthat facilitates and streamlines the mortgage originations process.

    “Its primary offering, Encompass, is a cloud-based one-stop shop for mortgage originators, allowing them to manage the loan process from start to finish,” Moser says. And by streamlining the process, Ellie Mae’s Encompass “increases efficiency and loan quality, reduces documentation errors, and helps keep everyone out of regulatory trouble.”

    With trailing revenues just below $250 million, Moser pegs the market opportunity as a $5 billion pie, and thinks ELLI will prove to be one of the best stocks to buy for 2016.

  • [By Lee Jackson]

    These companies also reported insider selling last week:Corcept Therapeutics Inc. (NASDAQ: CORT), Customers Bancorp Inc. (NYSE: CUBI), Ellie Mae Inc. (NYSE: ELLI), Fiserv Inc. (NASDAQ: FISV) and Ulta Beauty Inc. (NASDAQ: ULTA).

  • [By Brian Stoffel]

    HR and payroll specialist Paycom Software (NYSE:PAYC), mortgage software provider Ellie Mae (NYSE:ELLI), and cloud computing king for drug companies Veeva Systems (NYSE:VEEV) are the three best software companies you could buy in 2017. They share three key traits that any investor can love: high switching costs, blazing growth rates, and founders or CEOs with lots of skin in the game.

stock market today chart: Regeneron Pharmaceuticals, Inc.(REGN)

Advisors’ Opinion:

  • [By Chris Lange]

    Shares of Amgen Inc. (NASDAQ: AMGN) saw a handy gain to close out the week after the company won a Delaware court ruling that blocked Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from selling their cholesterol-lowering drug in the United States. Essentially the court found that the drug Praluent actually infringed upon Amgens patents for its rival treatment Repatha.

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) tumbled to the bottom of the S&P 500 today after a judge said the company could be forced to stop selling an anti-cholesterol drug due to violating an Amgen (AMGN) patent.

    Agence France-Presse/Getty Images

    Regeneron Pharmaceuticalsdropped 5.8% to $358.68 today, while the S&P 500 rose 0.4% to 2,276.98.

    Chardan’sGbola Amusa takes a victory lap:

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

    While the loss is bad news for Regeneron, Barron’s Johanna Bennettargues that it could herald a comeback for Amgen.

    Regeneron’s market capitalization fell to $38.5 billion today from $40.2 bil

  • [By Ben Levisohn]

    After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) soared to the top of the S&P 500 today after a competitor’s competing drug failed a Phase 3 trial.

    Getty Images

    Regenerongained 3.8% to $387.10 today, while the S&P 500 declined 0.1% to 2,256.96.

    RBC’s Adnan Butt and Michael Yee offer their take:

    Two Phase 3 studies comparing Ophthotechs (OPHT) Fovista plus Lucentis to Lucentis alone did not meet the primary endpoint of demonstrating a better vision for the combination at 12 months. The improvements were 10.24 letters for the combo vs. 10.01 for Lucentis when the two Phase 3s were combined. Individually, one Phase 3 showed combo improvement of 10.74 letters vs. 9.82 letters alone and the second 9.91 letters vs. 10.36 letters with Lucentis alone. A third Phase 3 study combining Fovista with Eylea or Avastin is ongoing…

    Big overhang removed; [Regeneron] shares should be up and then continue to rise with the focus moving to dupilumab. Overhang was that Fovista success and approval could disrupt the market for Eylea as more docs tried combining nearly free Avastin (off-label) with Fovista to improve outcomes with patients. We had always argued that even under that scenario Eylea would be used since it is the most potent agent. We are buyers at current level especially ahead of the upcoming dupilumab launch.

    Regeneron’s market capitalization rose to $51.5 billion today from $39.3 billion yesterday. It reported net income of $636 million on sales of $4.1 billion in 2015.

stock trading forum

Yesterday’s upbeat report on consumer spending and income in the US provides fresh support for last week’s moderately hawkish comments from Fed officials, who hinted that another interest rate hike is near, perhaps as early as next month’s Federal Open Market Committee (FOMC) meeting. Yet, support for pricing in a new round of policy tightening is modest at best via Treasury yields. Is that because job growth is expected to slow in this Friday’s employment report for July after two months of strong increases?

Total nonfarm payrolls are on track to rise by a moderate 175,000 in August, according to Econoday.com’s consensus forecast. That’s a decent gain, but it’s well below July’s increase of 255,000 and July’s 292,000 surge. Monthly data is noisy, and so it’s best to focus on the year-over-year trend. The August estimate translates into a 1.74% increase versus the year-earlier level, fractionally above July’s annual pace.

Job growth has clearly slowed in year-over-year terms, which isn’t terribly surprising for an economic recovery that’s celebrated its seventh birthday in June – one of the longest expansions on record, according to NBER data. The question is whether the Fed will feel compelled to continue squeezing rates when the trend for job growth is on a downward trajectory.

stock trading forum: Regeneron Pharmaceuticals, Inc.(REGN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) tumbled to the bottom of the S&P 500 today after a judge said the company could be forced to stop selling an anti-cholesterol drug due to violating an Amgen (AMGN) patent.

    Agence France-Presse/Getty Images

    Regeneron Pharmaceuticalsdropped 5.8% to $358.68 today, while the S&P 500 rose 0.4% to 2,276.98.

    Chardan’sGbola Amusa takes a victory lap:

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

    While the loss is bad news for Regeneron, Barron’s Johanna Bennettargues that it could herald a comeback for Amgen.

    Regeneron’s market capitalization fell to $38.5 billion today from $40.2 bil

  • [By Todd Campbell, Demitrios Kalogeropoulos, and Reuben Gregg Brewer]

    In the case of these three stocks, however, it may be worth taking a gamble. Our contributors think catalysts at Regeneron Pharmaceuticals (NASDAQ:REGN), Royal Dutch Shell (NYSE:RDS-B), and United Parcel Service (NYSE:UPS) can get them back to their winning ways. Read on to find out if these down-and-out stocks are right for your portfolio.

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) soared to the top of the S&P 500 today after a competitor’s competing drug failed a Phase 3 trial.

    Getty Images

    Regenerongained 3.8% to $387.10 today, while the S&P 500 declined 0.1% to 2,256.96.

    RBC’s Adnan Butt and Michael Yee offer their take:

    Two Phase 3 studies comparing Ophthotechs (OPHT) Fovista plus Lucentis to Lucentis alone did not meet the primary endpoint of demonstrating a better vision for the combination at 12 months. The improvements were 10.24 letters for the combo vs. 10.01 for Lucentis when the two Phase 3s were combined. Individually, one Phase 3 showed combo improvement of 10.74 letters vs. 9.82 letters alone and the second 9.91 letters vs. 10.36 letters with Lucentis alone. A third Phase 3 study combining Fovista with Eylea or Avastin is ongoing…

    Big overhang removed; [Regeneron] shares should be up and then continue to rise with the focus moving to dupilumab. Overhang was that Fovista success and approval could disrupt the market for Eylea as more docs tried combining nearly free Avastin (off-label) with Fovista to improve outcomes with patients. We had always argued that even under that scenario Eylea would be used since it is the most potent agent. We are buyers at current level especially ahead of the upcoming dupilumab launch.

    Regeneron’s market capitalization rose to $51.5 billion today from $39.3 billion yesterday. It reported net income of $636 million on sales of $4.1 billion in 2015.

  • [By Chris Lange]

    Shares of Amgen Inc. (NASDAQ: AMGN) saw a handy gain to close out the week after the company won a Delaware court ruling that blocked Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from selling their cholesterol-lowering drug in the United States. Essentially the court found that the drug Praluent actually infringed upon Amgens patents for its rival treatment Repatha.

  • [By Johanna Bennett]

    Shares of biotechnology giant Regeneron Pharmaceuticals (REGN) have climbed more than 4% today after Piper Jaffray analyst Ed Tenthoff upgraded the stock from a neutral to an overweight, with a $446 price target.

    The upgrade comes just a few days after the drug maker released soft guidance for 2017 and forecasts called for slowing sales of the eye drug Eylea.

    But Piper Jaffrays Tenthoff argues that anticipated approvals and deep pipeline should drive long-term value. Of particular importance: the atopic dermatitis drug Dupixent (dupilumab).

    We are confident in FDA approval of Dupixent (dupilumab) in moderate-to-severe atopic dermatitis by the March 29th PDUFA date and in Europe in late 2017. The Phase III LIBERTY ASTHMA QUEST study has fully enrolled 1,858 persistent asthma patients to 200mg and 300mg subcu Dupixent q2W. We look for data this year to enable an sBLA submission by YE:17. Regeneron is conducting two Phase III trials in nasal polyps and will initiate Phase III pediatric atopic dermatitis and asthma trials. The company will report data from a Phase II eosinophilic esophagitis study in 1H:17 and begin a Phase II food allergy study in 2H:17. The FDA has deemed Sanofi’s Le Trait facility “acceptable”. As a result, we anticipate the partners will refile on Kevzara (sarilumab) and could gain approval in 2Q:17. These two launches should turn Regeneron’s antibody alliance with Sanofi profitable.

    Todays news is the latest development in what has been a volatile time the drug maker. The shares have fallen sharply over the during the last three months, the result of a patent suit with Amgen (AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldnt be able to sell in the U.S. , But last week, a judge granted a stay that would allow Regeneron to sell Praluent. It also fueled a pop in its shares.

    The next day, however, Regeneron reported earnings, and while profits o

stock trading forum: Platform Specialty Products Corporation(PAH)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In his second “Executive Decision” segment, Cramer spoke with Rakesh Sachdev, CEO of Platform Specialty Products (PAH) , the agriculture and industrial roll-up company which has seen its shares double over the past 12 months. Yesterday, Platform Specialty delivered a two-cents-a-share earnings beat.

  • [By Lee Jackson]

    Platform Specialty Products Corp. (NYSE: PAH) had a well-known seller parting with a huge chunk of stock. Bill Ackman’s Pershing Square hedge fund sold a total of 2,285,888 shares of the stock at $8.78 apiece. The total for the sale was posted at $20 million.The company produces and sells specialty chemical products in the Americas, the Asia-Pacific and Europe. The stock closed last Friday at $8.52.

stock trading forum: Senior Housing Properties Trust(SNH)

Advisors’ Opinion:

  • [By Matthew Frankel]

    Healthcare real estate is just as defensive of an investment as net-lease retail, and has even more growth potential in the years ahead. One beaten-down healthcare REIT that I have my eye on in 2017 is Senior Housing Properties Trust (NASDAQ:SNH).

stock trading forum: Siebert Financial Corp.(SIEB)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Tuesday, our Under the Radar Moversnewsletter suggested shorting small cap discount brokerageSiebert Financial Corp (NASDAQ: SIEB):

    Siebert Financial has been on our watchlist for a while, overbought and toying with the idea of a pullback. We’re finally starting to see evidence that the weight of the gain is taking a toll. We’ve seen a string of lower highs following the last bullish gasp from the 9th. We’re going to assume that was the pivot point. (It has been so far, anyway.)

  • [By Lisa Levin]

    Siebert Financial Corp. (NASDAQ: SIEB) shares shot up 61 percent to $8.30 following news it will offer deeply discounted online trading of U.S. equities next year.

  • [By Cameron Saucier]

    Siebert (Nasdaq: SIEB) is a holding company that has a retail discount brokerage business through its subsidiary, Muriel Siebert & Co. SIEB rose 60% last month after it announced a purchasing agreement with Kennedy Cabot Acquisition. Under the agreement, Kennedy Cabot will purchase shares of SIEB. SIEB is currently trading at $3.37 per share and is up 157% YOY.

stock trading forum: MannKind Corporation(MNKD)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    MannKind Corp. (MNKD) has developed a drug, Afrezza, which is a new form of inhalable insulin that is proving to have many benefits over existing mealtime insulins for diabetics.  

  • [By James E. Brumley]

    When most investors think of diabetes stocks, names like Novo Nordisk A/S (ADR) (NYSE:NVO) and MannKind Corporation (NASDAQ:MNKD) come to mind. And well they should. Novo Nordisk is the biggest insulin company in the world, and while MannKind is relatively small, it’s a name that turns heads simply because it came up with an inhalable insulin that – after a slow start – is getting a little traction.

    In both cases though, the paradigm is the same one that was first used decades ago. That is, if a person isn’t making their own insulin, then it must be introduced externally. What if instead a diabetic’s glucose levels could be controlled by turning on the cells in their body responsible for processing that sugar? That’s the approach Cell MedX Corp (OTCMKTS:CMXC) is taking, using a relatively new but very compelling science.

    While chemical-based manufactured pharmaceuticals were largely the core of healthcare for well over the past century, it’s become clear that our bodies – right down to our cells – are also electrical in nature. Not only do they produce it, they need it to function properly. The FDA has even recently approved a therapeutic device that delivers mild electrical currents to and through an individual’s body as a means of treating pain. This “electromedicine” has also shown a certain degree of efficacy as a treatment for several illnesses, including cancer. Specifically, electrical currents have been demonstrated to force pleomorphic cancer microbes into hibernation, essentially making a cancerous cell a normal, healthy cell again. So, using an electrical current as a means of therapy for diabetics isn’t far-fetched at all. Indeed, it’s quite brilliant.

    As for how Cell MedX is using the idea, it’s actually quite simple. The device is called an eBalance. At first glance it just looks like another ordinary tablet computer. A closer inspection of the e-Balance device, however, makes it clear that it’s not just another tablet. It’

  • [By Peter Graham]

    The Q4 2016 earnings report for troubled small cap diabetes stock MannKind Corporation (NASDAQ: MNKD) is scheduled for after the market closes Thursday (March 16th). So far,MannKind Corporations novel rapid-acting inhaled insulin therapy Afrezza has been a disappointment for investors; and if that doesnt start to change, theMNKD could soon run out of money. For that reason, the Company has elevated short interest of 36.43% according to Highshortinterest.com.

  • [By Sean Williams]

    Last summer, my mind was fully set on short-selling shares (i.e., betting they go down) of drugmaker MannKind (NASDAQ:MNKD). My investment thesis was pretty straightforward: MannKind was eventually going to seek bankruptcy protection.

Top Low Price Stocks To Invest In Right Now

What happened

Shares of Rogers Corp. (NYSE:ROG) gained 19.9% in April 2017, according to data from S&P Global Market Intelligence.

So what

The company reported first-quarter results on April 26, sending share prices nearly 12% higher the next day. Rogers saw 27% year-over-year sales growth and 79% higher earnings, leaving analyst estimates far behind in both cases.

A Rogers engineer, hard at work on next-generation battery materials. Image source: Rogers.

Now what

Rogers shares have now gained 72% over the last 52 weeks, trading steadily near all-time highs. The maker of specialized materials used in battery systems and wireless antennas has consistently delivered solid earnings surprises over the last three years, often coupled with equally strong revenue wins.

This company is poised to continue making a killing in several emerging markets, including the Internet of Things and automotive computing. Best of all, Rogers is winning competitive contracts without resorting to pricing discounts. Trailing operating margins have increased from 12.4% to 14.2% over the last four quarters. In other words, clients are choosing Rogers over rival materials providers for other reasons than low prices, such as product quality and dependable ordering and delivery processes.

Top Low Price Stocks To Invest In Right Now: RetailMeNot, Inc.(SALE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of RetailMeNot Inc (NASDAQ: SALE) got a boost, shooting up 12 percent to $8.42. RetailMeNot announced after Thursday’s close it has entered into an agreement to acquire GiftCard Zen, a secondary marketplace for gift cards. The company reported preliminary Q1 revenue of $54 million to $54.5 million and FY16 revenue of $228 million to $241 million.

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, RetailMeNot (NASDAQ:SALE) and SUPERVALU (NYSE:SVU) attracted heavy investor interest following merger and acquisition news.

Top Low Price Stocks To Invest In Right Now: Astrotech Corporation(ASTC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Astrotech Corp (NASDAQ: ASTC) shares shot up 70 percent to $4.83. Astrotech reported that it has completed its successful 1st Detect demo with Department of Homeland Security and Transportation Security Administration personnel.

  • [By Lisa Levin]

    Astrotech Corp (NASDAQ: ASTC) shares shot up 60 percent to $4.37. Astrotech reported that it has completed its successful 1st Detect demo with Department of Homeland Security and Transportation Security Administration personnel.

Top Low Price Stocks To Invest In Right Now: Regeneron Pharmaceuticals, Inc.(REGN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) soared to the top of the S&P 500 today after a competitor’s competing drug failed a Phase 3 trial.

    Getty Images

    Regenerongained 3.8% to $387.10 today, while the S&P 500 declined 0.1% to 2,256.96.

    RBC’s Adnan Butt and Michael Yee offer their take:

    Two Phase 3 studies comparing Ophthotechs (OPHT) Fovista plus Lucentis to Lucentis alone did not meet the primary endpoint of demonstrating a better vision for the combination at 12 months. The improvements were 10.24 letters for the combo vs. 10.01 for Lucentis when the two Phase 3s were combined. Individually, one Phase 3 showed combo improvement of 10.74 letters vs. 9.82 letters alone and the second 9.91 letters vs. 10.36 letters with Lucentis alone. A third Phase 3 study combining Fovista with Eylea or Avastin is ongoing…

    Big overhang removed; [Regeneron] shares should be up and then continue to rise with the focus moving to dupilumab. Overhang was that Fovista success and approval could disrupt the market for Eylea as more docs tried combining nearly free Avastin (off-label) with Fovista to improve outcomes with patients. We had always argued that even under that scenario Eylea would be used since it is the most potent agent. We are buyers at current level especially ahead of the upcoming dupilumab launch.

    Regeneron’s market capitalization rose to $51.5 billion today from $39.3 billion yesterday. It reported net income of $636 million on sales of $4.1 billion in 2015.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

  • [By Ben Levisohn]

    After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:

Top Low Price Stocks To Invest In Right Now: Federated Investors, Inc.(FII)

Advisors’ Opinion:

  • [By Gregg Greenberg]

     Stocks of Federated Investors (FII) fell approximately 9% in 2015, yet Oja expects a big turnaround in 2016, once again due to the prospect of higher rates ahead. 

     

    "The money market fund business, which is unprofitable now, should become more profitable as rates rise because Federated has to reimburse for the servicing fees for these funds," said Oja, who also admires the fund company’s 3.5% dividend yield. 

     

    Oja added that Federated also has a "good core business of equity and fixed-income asset management." 

Best High Tech Stocks To Own For 2018

Small cap mobile gaming stock SPYR Inc (OTCMKTS: SPYR) has just signed a licensing agreement with CBS Consumer Products that will allow the incorporation of intellectual property (IP) from various Star Trek television series in future updates to and expansions of its game Pocket Starships. How much could that be worth to SPYR Inc? Consider the following net worthestimates published by Fortune last summer for the actors/actresses who were made famous by the original series (thus, guaranteed recurring income from the fan convention circuit) and just how much theyhave made mostly from having once been in the series:

William Shatner, $100 million Leonard Nimoy, $45 million DeForest Kelley (Dr. McCoy), $5 million James Doohan (Lt. Commander Montgomery Scotty Scott), $7 million Nichelle Nichols (Uhura), $8 million George Takei (Hikaru Sulu), $12 million Walter Koenig (Ensign Pavel Chekov), $8 million Majel Barrett (Nurse Chapel + computer voice), $60 million-plus (she was also wife of show creator Gene Roddenberry)

Creator Gene Roddenberry also made his estimated $500 million fortune off of his creation and its many spin-offs while Rick Berman, who was the executive producer of several later series, then made a comfortable living off the franchise.

Best High Tech Stocks To Own For 2018: State Bank Financial Corporation.(STBZ)

Advisors’ Opinion:

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    J P Morgan Chase & Co (NYSE: JPM): Free Stock Analysis Report
     
    Comerica Incorporated (NYSE: CMA): Free Stock Analysis Report
     
    Wells Fargo & Company (NYSE: WFC): Free Stock Analysis Report
     
    Citigroup Inc. (NYSE: C): Free Stock Analysis Report
     
    Wintrust Financial Corporation (NASDAQ: WTFC): Free Stock Analysis Report
     
    Synovus Financial Corp. (NYSE: SNV): Free Stock Analysis Report
     
    State Bank Financial Corporation. (NASDAQ: STBZ): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

Best High Tech Stocks To Own For 2018: Regeneron Pharmaceuticals, Inc.(REGN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) soared to the top of the S&P 500 today after a competitor’s competing drug failed a Phase 3 trial.

    Getty Images

    Regenerongained 3.8% to $387.10 today, while the S&P 500 declined 0.1% to 2,256.96.

    RBC’s Adnan Butt and Michael Yee offer their take:

    Two Phase 3 studies comparing Ophthotechs (OPHT) Fovista plus Lucentis to Lucentis alone did not meet the primary endpoint of demonstrating a better vision for the combination at 12 months. The improvements were 10.24 letters for the combo vs. 10.01 for Lucentis when the two Phase 3s were combined. Individually, one Phase 3 showed combo improvement of 10.74 letters vs. 9.82 letters alone and the second 9.91 letters vs. 10.36 letters with Lucentis alone. A third Phase 3 study combining Fovista with Eylea or Avastin is ongoing…

    Big overhang removed; [Regeneron] shares should be up and then continue to rise with the focus moving to dupilumab. Overhang was that Fovista success and approval could disrupt the market for Eylea as more docs tried combining nearly free Avastin (off-label) with Fovista to improve outcomes with patients. We had always argued that even under that scenario Eylea would be used since it is the most potent agent. We are buyers at current level especially ahead of the upcoming dupilumab launch.

    Regeneron’s market capitalization rose to $51.5 billion today from $39.3 billion yesterday. It reported net income of $636 million on sales of $4.1 billion in 2015.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

  • [By Ben Levisohn]

    It hasn’t been an easy time for investors inRegeneron Pharmaceuticals (REGN) recently…and today’s price action is likely to reinforce the sense of whiplash they must be feeling.

    Agence France-Presse/Getty Images

    What do I mean? Regeneron’s dropped 14% during the last three months, the result of a patent suit with Amgen(AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldn’t be able to sell in the U.S.Then last night, there was finally good news: Ajudge ordered a stay, which would allow Regeneron to sell Praluent, and resulted in a 2% pop in its shares last night after the market close. But then Regeneron reported earnings, and while profits of $3.04 cents a share metthe Street consensus, Regeneron missed on sales and offered disappointing guidance. That caused Regeneron shares to sink 2.1% in pre-open trading.

    Fast forward to this afternoon, and and now they’re up nearly 3%. Credit Suisse analyst Alethia Young and team explain why the injunction outweighs the earnings:

    Company issued Eylea guidance for 2017- they guided single digit
    percentage growth over 2016. Consensus had been for 12% growth and we
    had modeled 11% growth.

    EPS for 4Q came in at $3.04 in line with $3.04 consensus. Since the company has already provided OpEx guidance for 2017 and the Eylea 4Q estimate ahead of today we think earnings are less of a focus.

    We are curious where in the single digit percentage growth for Eylea the company means- 9% YoY growth wouldnt be too far from consensus vs. 3%
    growth…

    As we wrote last night, we would expect shares to trade up due to the injunction stay. We would expect shares to be up 2-4% from the injunction stay, but the effect might be muted somewhat by the Eylea guide. We would guess shares might be up 1 to 3% today.

    Shares ofRegeneron Pharmaceuticals have gained 2.8% to $363.04 at 1:57 p.m. today, while the iS

Best High Tech Stocks To Own For 2018: Seadrill Limited(SDRL)

Advisors’ Opinion:

  • [By Jason Hall]

    Shares of a number of offshore drilling stocks are up big on Friday following the announcement of Q4 earnings fromNoble Corporation Ordinary Shares (NYSE:NE). Noble’s shares are leading the way today, up over 12% as of 2:50 p.m. EST, butSeadrill Ltd(NYSE:SDRL) stock is also up more than 10%, whileENSCO PLC(NYSE:ESV) andDiamond Offshore Drilling Inc(NYSE:DO) are both up around 5%:

  • [By Lisa Levin]

    Seadrill Ltd (NYSE: SDRL) shares dropped 58 percent to $0.706. Seadrill and its banking group agreed to extend a series of key dates as part of restructuring efforts.

  • [By Chris Lange]

    Seadrill Ltd. (NYSE: SDRL) will to share its latest quarterly earnings on Tuesday. The consensus estimates call for $0.22 in EPS and $721.81 million in revenue. Shares were at $2.35 in Friday trading, in a 52-week range of $1.57 to $7.49. The consensus price target is $1.96.

  • [By Paul Ausick]

    SeaDrill Ltd. (NYSE: SDRL) dropped about 27.5% on Friday to record a new 52-week low of $1.21 against a high of $7.49. The stock closed at $1.67 on Thursday. Volume was more than double the daily average of around 14 million shares. The company had no specific news Friday.

Best High Tech Stocks To Own For 2018: Silicom Ltd(SILC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Silicom Ltd. (NASDAQ: SILC) shares were also up, gaining 17 percent to $45.45. Silicom reported a major new design win with $17 million in purchase orders.

Best High Tech Stocks To Own For 2018: Eastman Kodak Company(KODK)

Advisors’ Opinion:

  • [By Lee Jackson]

    Another famous American company caught a seller last week. Eastman Kodak Co.(NYSE: KODK) had a 10% owner selling shares. Blue Mountain Capital sold a total of 1,353,653 shares, and prices ranged from $11.54 to $11.75 a share. The total for the sale was set at $16 million. The shares closed Friday at $11.50, in a 52 week range of $10 to $17.30. There was no consensus target as the stock is not followed on Wall Street.

  • [By William Patalon III]

    One of those analysts was a gent named Michael W. Ellmann, a onetime Shakespearian literature professor who’d become a securities analyst for Wertheim Schroder & Co. in New York. Michael was covering Eastman Kodak Co. (NYSE: KODK) for Schroder when I took over the Kodak beat for Gannett Newspapers, and we became fast friends.

  • [By William Patalon III]

    The first trade spat that I covered during my newspaper days was one back in the mid-1990s that pitted Eastman Kodak Co. (NYSE: KODK) against Fujifilm Holdings Corp. (OTC ADR: FUJIY).

Best High Tech Stocks To Own For 2018: Blackrock Global(BOE)

Advisors’ Opinion:

  • [By Robert Rapier]

    Whiting Petroleum (WLL) is one of Continental’s biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.